ストックスクリーナーアプリを入手
2.42
9.01%
0.20
アフターアワーズ：
2.43
0.01
+0.41%
前日終値:
$2.22
開ける：
$2.365
24時間の取引高:
293.58K
Relative Volume:
0.22
時価総額：
$171.84M
収益：
$20.76M
当期純損益:
$-132.49M
株価収益率:
-0.9064
EPS:
-2.67
ネットキャッシュフロー:
$-108.55M
1週間 パフォーマンス:
+19.80%
1か月 パフォーマンス:
+64.63%
6か月 パフォーマンス:
-35.29%
1年 パフォーマンス:
-62.65%
1日の値動き範囲:
$2.3601
$2.44
1週間の範囲:
$1.92
$2.705
52週間の値動き範囲:
$1.085
$7.3573
C 4 Therapeutics Inc Stock (CCCC) Company Profile
CCCC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.42 | 157.64M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Equal-Weight |
| 2024-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-12-13 | アップグレード | Stifel | Hold → Buy |
| 2023-02-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-04-28 | 開始されました | Credit Suisse | Underperform |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-10 | 開始されました | JP Morgan | Overweight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-11-23 | 開始されました | BofA Securities | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-27 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-27 | 開始されました | Jefferies | Buy |
すべてを表示
C 4 Therapeutics Inc (CCCC) 最新ニュース
What analysts say about C4 Therapeutics Inc. stockFree Technical Analysis Support - Autocar Professional
C4 Therapeutics Inc. Stock Analysis and ForecastSkyrocketing returns - Autocar Professional
What drives C4 Therapeutics Inc. stock priceHigh-octane investment gains - Autocar Professional
Is C4 Therapeutics Inc. a good long term investmentDouble-digit growth - printweek.in
What analysts say about C4 Therapeutics Inc. stock outlookMinimized Risk Maximum Return - beatles.ru
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - ADVFN Brasil
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) - The Manila Times
C4 Therapeutics Bets On New Cancer Drug And Big Partnerships - Finimize
Molecular Glue Degrader Market Top Companies StudyC4 - openPR.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Marriott (MAR) names Jennifer Mason CFO as Kathleen Oberg retires | CCCC SEC FilingForm 4 - Stock Titan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics (CCCC) Shares Soar 12.06% on FDA Designations - AInvest
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics Stock Surges: What Now? - StocksToTrade
Aligos Therapeutics Grants 2,100 Shares in Stock Options to New Hires with 4-Year Vesting Terms - Stock Titan
C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Top Penny Stocks To Watch In July 2025 - Yahoo Finance
C4 Therapeutics (CCCC) Soars 26.90% on Positive Clinical Trial Results - AInvest
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc.(NasdaqGS: CCCC) dropped from Russell 3000E Index - MarketScreener
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C 4 Therapeutics Inc (CCCC) 財務データ
収益
当期純利益
現金流量
EPS
C 4 Therapeutics Inc (CCCC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Boyle Scott N | Chief Business Officer |
Feb 14 '25 |
Sale |
3.15 |
490 |
1,544 |
110,842 |
4.91%
0.25%
大文字化:
|
ボリューム (24 時間):